Skip to main content

schizophrenia

Team finds how error and reward signals are organized within cerebral cortex

Jan. 14, 2019—Psychiatrists diagnose people with schizophrenia, ADHD, bipolar disorder and other mental illnesses by spending time with them, looking for the particular behavior symptoms of each. What follows can be a hit-or-miss series of medications and dosages until disruptive behaviors go away. By deciphering the circuitry of the medial frontal cortex – an area beneath the...

Read more


People with schizophrenia experience emotion differently from others, ‘body maps’ show

Dec. 21, 2018—Vanderbilt University researchers are working to understand how people with schizophrenia experience emotion through their bodies.

Read more


Shared genetics may shape treatment options for certain brain disorders

Jun. 14, 2018—Symptoms of schizophrenia and bipolar disorder, including psychosis, depression and manic behavior, have both shared and distinguishing genetic factors, an international consortium led by researchers from Vanderbilt University and Virginia Commonwealth University is reporting.

Read more


Brain connections in schizophrenia

Mar. 9, 2018—Brain imaging studies have implicated the connection between two brain regions in the pathophysiology of schizophrenia.

Read more


Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

Read more


Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

Read more


Investigational new drug for Alzheimer’s scheduled for first study in humans

Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

Read more


Researchers eye potential schizophrenia ‘switch’

Sep. 15, 2016—Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.

Read more


Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt

Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.

Read more


Putting schizophrenia to bed

Mar. 21, 2016—A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.

Read more


Brain circuitry in psychosis

Aug. 21, 2015—Functional magnetic resonance imaging has revealed faulty circuits between the thalamus – a central hub of brain activity – and other brain regions.

Read more


Signals of schizophrenia

Jul. 9, 2015—Vanderbilt researchers have discovered a possible molecular mechanism of schizophrenia that could lead to new treatments for the disorder.

Read more


Upcoming Events

MORE EVENTS »